Late-onset isolated adrenocorticotropic hormone deficiency caused by nivolumab: a case report
出版年份 2019 全文链接
标题
Late-onset isolated adrenocorticotropic hormone deficiency caused by nivolumab: a case report
作者
关键词
Anti-programmed cell death protein 1 antibody, Anti-cytotoxic T-lymphocyte-associated protein 4 antibody, Nivolumab, Isolated adrenal deficiency, Thyroid dysfunctions
出版物
BMC Endocrine Disorders
Volume 19, Issue 1, Pages -
出版商
Springer Nature
发表日期
2019-02-19
DOI
10.1186/s12902-019-0335-x
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer
- (2018) Charles S. Fuchs et al. JAMA Oncology
- Isolated ACTH deficiency probably induced by autoimmune-related mechanism evoked with nivolumab
- (2017) Keiko Kitajima et al. JAPANESE JOURNAL OF CLINICAL ONCOLOGY
- Long-lasting shrinkage in tumor mass after discontinuation of nivolumab treatment
- (2017) Hideharu Kimura et al. LUNG CANCER
- Nivolumab-induced hypophysitis in a patient with advanced malignant melanoma
- (2016) Yudai Okano et al. ENDOCRINE JOURNAL
- Nivolumab-induced thyroid dysfunction
- (2016) Ryota Tanaka et al. JAPANESE JOURNAL OF CLINICAL ONCOLOGY
- Isolated adrenocorticotropic hormone deficiency possibly caused by nivolumab in a metastatic melanoma patient
- (2016) Taku Fujimura et al. JOURNAL OF DERMATOLOGY
- Case of hypophysitis caused by nivolumab
- (2016) Masashi Ishikawa et al. JOURNAL OF DERMATOLOGY
- Isolated adrenocorticotropic hormone deficiency associated with nivolumab therapy
- (2016) Atsushi Narahira et al. JOURNAL OF DERMATOLOGY
- Case of type 1 diabetes associated with less-dose nivolumab therapy in a melanoma patient
- (2016) Yukiko Teramoto et al. JOURNAL OF DERMATOLOGY
- Fulminant type 1 diabetes mellitus with anti-programmed cell death-1 therapy
- (2016) Masahide Okamoto et al. Journal of Diabetes Investigation
- Anti–PD-1 and Anti–PDL-1 Monoclonal Antibodies Causing Type 1 Diabetes
- (2015) Mahnaz Mellati et al. DIABETES CARE
- Serological aggravation of autoimmune thyroid disease in two cases receiving nivolumab
- (2015) Tomohiko Narita et al. JOURNAL OF DERMATOLOGY
- Nivolumab in Previously Untreated Melanoma without BRAF Mutation
- (2015) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Systemic High-Dose Corticosteroid Treatment Does Not Improve the Outcome of Ipilimumab-Related Hypophysitis: A Retrospective Cohort Study
- (2014) L. Min et al. CLINICAL CANCER RESEARCH
- Ipilimumab-Induced Hypophysitis: A Detailed Longitudinal Analysis in a Large Cohort of Patients With Metastatic Melanoma
- (2014) Alexander T. Faje et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab
- (2014) Suzanne L. Topalian et al. JOURNAL OF CLINICAL ONCOLOGY
- Endocrine Side Effects Induced by Immune Checkpoint Inhibitors
- (2013) Salvatore Maria Corsello et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Phase III Randomized Clinical Trial Comparing Tremelimumab With Standard-of-Care Chemotherapy in Patients With Advanced Melanoma
- (2013) Antoni Ribas et al. JOURNAL OF CLINICAL ONCOLOGY
- Management of Immune-Related Adverse Events and Kinetics of Response With Ipilimumab
- (2012) Jeffrey S. Weber et al. JOURNAL OF CLINICAL ONCOLOGY
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
- (2012) Suzanne L. Topalian et al. NEW ENGLAND JOURNAL OF MEDICINE
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
- (2010) F. Stephen Hodi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Control of peripheral T-cell tolerance and autoimmunity via the CTLA-4 and PD-1 pathways
- (2008) Brian T. Fife et al. IMMUNOLOGICAL REVIEWS
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now